A previous study of NSCLC patients with KEAP1/NFE2L2 mutations from Memorial Sloan Kettering Cancer Center database, has shown that KEAP1/NFE2L2 mutations were associated with inferior overall survival but improved survival in the KEAP1-NFE2L2 mutant tumors treated with immunotherapy compared with other treatments (14). The gene discussed is NFE2L2; the disease is cancer.